First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2051-1426

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy ; volume:7 ; number:1 ; day:3 ; month:5 ; year:2019 ; pages:1-6 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (3.5.2019), 1-6, 12.2019

Classification: Medizin, Gesundheit

Creator: Zhou, Yixin
Lin, Zuan
Zhang, Xuanye
Chen, Chen
Zhao, Hongyun
Hong, Shaodong
Zhang, Li

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40425-019-0600-6

URN: urn:nbn:de:101:1-2019052702294513535821

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:52 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Zhou, Yixin
Lin, Zuan
Zhang, Xuanye
Chen, Chen
Zhao, Hongyun
Hong, Shaodong
Zhang, Li
SpringerLink (Online service)

Other Objects (12)

Pembrolizumab

$Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression$

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

How do behavior problems change over time in childhood? Evidence from the early childhood longitudinal study

Synthesis of Ambient Copolymerization CQAS Hydrogel Composite Membrane with Enhanced Antifouling

Pembrolizumab for all

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer

Pembrolizumab: The Nut Cracker

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Pembrolizumab

$Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression$

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

How do behavior problems change over time in childhood? Evidence from the early childhood longitudinal study

Synthesis of Ambient Copolymerization CQAS Hydrogel Composite Membrane with Enhanced Antifouling

Pembrolizumab for all

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer

Pembrolizumab: The Nut Cracker

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Pembrolizumab

$Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression$

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

How do behavior problems change over time in childhood? Evidence from the early childhood longitudinal study

Synthesis of Ambient Copolymerization CQAS Hydrogel Composite Membrane with Enhanced Antifouling

Pembrolizumab for all

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer

Pembrolizumab: The Nut Cracker

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Pembrolizumab

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

How do behavior problems change over time in childhood? Evidence from the early childhood longitudinal study

Synthesis of Ambient Copolymerization CQAS Hydrogel Composite Membrane with Enhanced Antifouling

Pembrolizumab for all

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer

Pembrolizumab: The Nut Cracker

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Pembrolizumab

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

How do behavior problems change over time in childhood? Evidence from the early childhood longitudinal study

Synthesis of Ambient Copolymerization CQAS Hydrogel Composite Membrane with Enhanced Antifouling

Pembrolizumab for all

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer

Pembrolizumab: The Nut Cracker

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Pembrolizumab

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

How do behavior problems change over time in childhood? Evidence from the early childhood longitudinal study

Synthesis of Ambient Copolymerization CQAS Hydrogel Composite Membrane with Enhanced Antifouling

Pembrolizumab for all

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer

Pembrolizumab: The Nut Cracker

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Related objects

Reset password